Physician profile
Alicia Cleaver
NPI 1730409939
$3,455.86
in general payments reported to CMS, 2019-2025
34 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $419 · 2021: $837 · 2022: $557 · 2023: $296 · 2024: $661 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,129.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $551.45 | 2019-2023 | Mavyret, Vraylar |
| Pfizer INC. | $500.11 | 2019-2025 | |
| Amgen INC. | $410.18 | 2019-2024 | Repatha, Otezla |
| Novo Nordisk INC | $394.23 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $228.46 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $204.44 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.61 | 2020-2023 | Jardiance |
| Lilly USA, LLC | $150.26 | 2021-2024 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $100.06 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.39 | 2020-2022 | |
| Mylan Specialty L.P. | $71.39 | 2019 | |
| Amarin Pharma, INC. | $56.15 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $53.70 | 2022-2024 | Rexulti |
| Allergan, INC. | $51.98 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $38.78 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $31.61 | 2020 | |
| Boston Scientific Corporation | $30.89 | 2025 | General - Therapies, Wavewriter Alpha Prime 16 |
| Astrazeneca Pharmaceuticals LP | $30.10 | 2024-2025 | Airsupra |
| Philips North America LLC | $26.82 | 2022-2025 | Ecc Solutions |
| Nevro Corp. | $25.36 | 2022 | |
| Biosense Webster, INC. | $23.70 | 2025 | Carto 3 |
| Astellas Pharma US INC | $23.47 | 2024 | Veozah |
| Cranial Technologies, INC | $21.27 | 2021 | |
| Dexcom, INC. | $19.30 | 2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $18.88 | 2024 | Omnipod |
| Exact Sciences Corporation | $18.12 | 2024 | Cologuard Collection Kit |
| Lundbeck LLC | $16.58 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.78 | 2021 | |
| Shield Therapeutics INC | $15.75 | 2023 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $13.05 | 2021 | |
| Eisai INC. | $12.71 | 2021 | |
| Glaxosmithkline, LLC. | $12.65 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.81 | 2019 | |
| Sanofi Pasteur INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicia Cleaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.